1	Limited induction of lung-resident memory T cell responses against
2	SARS-CoV-2 by mRNA vaccination
3	
4	Daan K.J. Pieren ¹ , Sebastián G. Kuguel ¹ , Joel Rosado ² , Alba G. Robles ¹ , Joan Rey-Cano ¹ , Cristina
5	Mancebo ¹ , Juliana Esperalba ³ , Vicenç Falcó ¹ , María J. Buzón ¹ , Meritxell Genescà ^{1*}
6	
7	Affiliations
8 9	¹ Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129,
10	08035 Barcelona, Spain;
11	² Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca (VHIR), Vall
12 13	d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;
14	³ Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall
15	d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-
16	129,08035 Barcelona, Spain.
17	
18	Corresponding author:
19	Meritxell Genescà
20	Vall d'Hebron Research Institute (VHIR)
21	Infectious Disease Department
22	119-129 Passeig Vall d'Hebron, 08035 Barcelona, Spain
23	Phone: +34 93 274 6200
24	Email: <u>meritxell.genesca@vhir.org</u>
25 26	
20 27	
27	
20 29	
30	
31	
32	
33	
34	
35	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 Abstract

Resident memory T cells (T_{RM}) present at the respiratory tract may be essential to enhance early 37 38 SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term antigen 39 (Ag)-specific T_{RM} are detectable beyond 11 months in the lung of convalescent COVID-19 patients 40 after mild and severe infection, it is unknown if mRNA vaccination encoding for the SARS-CoV-2 41 S-protein can induce this frontline protection. We found that the frequency of CD4⁺ T cells 42 secreting interferon (IFN) γ in response to S-peptides was variable but overall similar in the lung 43 of mRNA-vaccinated patients compared to convalescent-infected patients. However, in 44 vaccinated patients, lung responses presented less frequently a T_{RM} phenotype compared to 45 convalescent infected individuals and polyfunctional CD107a⁺ IFN γ^+ T_{RM} were virtually absent. Thus, a robust and broad T_{RM} response established in convalescent-infected individuals may be 46 47 advantageous in limiting disease if the virus is not blocked by initial mechanisms of protection, 48 such as neutralization. Still, mRNA vaccines might induce responses within the lung parenchyma, 49 potentially contributing to the overall disease control.

50 Introduction

51 The COVID-19 pandemic continues, and many countries face multiple resurgences. While 52 vaccines to limit SARS-CoV-2 infection rapidly emerged providing high protection from COVID-53 19, more insight into the mechanisms of protection induced by available vaccines is still needed. 54 The level of vaccine-induced neutralizing antibodies has been shown to correlate with protection 55 from symptomatic infection; however, predicted antibody-mediated vaccine efficacy declines over 56 time¹. Moreover, many viral variants of concern (VOC) can significantly evade humoral immunity, 57 vet cellular responses induced by vaccines show strong cross-protection against these variants². 58 ³, supporting the idea that cellular responses largely contribute to disease control ⁴. In fact, 59 preexisting cross-reactive memory T cells and early Nucleocapsid (N) responses against 60 coronaviruses are associated with protection from SARS-CoV-2 infection ^{5, 6}.

61 Further, SARS-CoV-2 infection induces robust cellular immunity detectable beyond 10 months after infection in peripheral blood ⁷, and as T_{RM} in the lung ⁸, and the number of SARS-CoV-2-62 specific T_{RM} in the lung correlates with clinical protection ⁹. Vaccination against SARS-CoV-2 63 64 using BTN162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) vaccines has been reported to 65 induce CD4⁺ and CD8⁺ T-cell responses in peripheral blood ^{10, 11}. Moreover, the IFN_γ T-cell response to SARS-CoV-2 S-peptides, one of the main antiviral factors measured as a readout, 66 further increased after boosting¹¹. However, current studies only address vaccine-induced SARS-67 68 CoV-2 specific T-cell responses in peripheral blood and whether mRNA vaccines also elicit 69 SARS-CoV-2-specific long-term T_{RM} cells in the lung remains to be established.

To this end, we determined the presence of SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in 26 paired peripheral blood and lung cross-sectional samples from: I.) uninfected unvaccinated individuals (Ctrl, n=5), II.) unvaccinated long-term SARS-CoV-2 convalescent individuals (Inf, n=9, convalescent for a median of 304 days [183-320 IQR]), III.) uninfected and long-term twodose vaccinated individuals (Vx2, n=7, a median of 206 days [184-234] after the second dose),

75	and IV.) uninfected and short-term three-dose vaccinated individuals (Vx3, n=5, a median of 52
76	days [42-54] after the third dose or boost). Whereas our data showed that S-specific T cells can
77	be detected in the lung of mRNA-vaccinated individuals up to 8 months after immunization, lung
78	responses in vaccinated patients presented less frequently a T_{RM} phenotype and polyfunctional
79	T_{RM} expressing IFN γ and CD107a were essentially absent compared to convalescent patients.
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	
	4

101 Results

102 Cohort characteristics

103 Paired cross-sectional peripheral blood and healthy tissue areas obtained from patients 104 undergoing lung resection for differing oncologic reasons were studied. Patient characteristics are 105 summarized in Supplemental Table 1. In order to confirm the SARS-CoV-2 status of each patient, 106 we analyzed total immunoglobulin (Ig) or IgG levels against N and Spike (S) proteins respectively, 107 which discriminated Ctrl (negative for N and S), Inf patients (positive for N and S) and vaccinated 108 groups (negative for N and positive for S; Supplemental Table 1). Furthermore, the viral 109 neutralization titer was determined against the SARS-CoV-2 Omicron variant using a pseudovirus 110 neutralization assay and, as expected ^{10, 11}, a positive correlation between neutralization and S-111 IgG titers was detected (Spearman r = 0.72, P = 0.0016; Supplemental Figure 1A). In addition to 112 the absence of neutralization of the Omicron variant in plasma of the Ctrl group, 2 out of 7 patients 113 (28%) in the Inf group and from 1 out of 6 patients (17%) in the Vx2 group failed to neutralize the 114 virus, whereas all patients in the Vx3 group were able to neutralize this variant (Supplemental 115 Table 1). The fact that we mostly studied elderly patients could certainly determine the overall 116 response and, indeed there was a negative correlation between older age and neutralizing 117 capacity for the Inf group (Spearman r = -0.88, P = 0.01; Supplemental Figure 1B) and the same 118 trend was observed for the Vx2 group (Spearman r = -0.72, P = 0.10; Supplemental Figure 1C). 119 This relationship was less evident between age and S-IgG titers (Supplemental Figure 1D, E), yet 120 examples in larger cohorts exist ¹⁰. Instead, S-IgG titers from all groups negatively correlated with sample timing (Spearman r = -0.61, P = 0.010; Supplemental Figure 1F), a correlation that was 121 122 also observed for total Ig against N in the Inf group (Spearman r = -0.88, P = 0.009; Supplemental 123 Figure 1G), which agrees with antibody titers decay ^{10, 11, 12}.

124

Recent mRNA booster vaccination elicits S-specific CD4⁺ T cells similar to convalescent infection

128 To address cellular immune responses, we stimulated fresh peripheral blood mononuclear cells 129 (PBMC) and lung-derived cellular suspensions with overlapping Membrane (M), N and S peptide 130 pools and determined the intracellular expression of IFN_γ, interleukin (IL)-4, and IL-10, along with 131 the degranulation marker CD107a in CD4⁺ and CD8⁺ T cells (Supplemental Figure 2A), as 132 previously described ⁸. We found detectable circulating IFN_γ-secreting Ag-specific CD4⁺ T cells 133 responding to all proteins in the blood of Inf patients, which was significantly higher compared to 134 the Ctrl, Vx2, and Vx3 groups for M and N peptides (Figure 1A, B). In contrast, for S peptides, the 135 Inf group only showed higher frequencies of IFN γ^+ CD4⁺ T cells compared to the Ctrl group, 136 indicating an increase induced by vaccination in the blood of Vx2 and Vx3 groups. However, only 137 two Vx2 patients showed detectable frequencies of S-specific CD4⁺ T cells in blood, while recently 138 boosted Vx3 patients displayed an overall increase reaching statistical significance compared to 139 the Ctrl group (Figure 1B). In contrast to CD4⁺ T cells, the frequencies of IFNγ⁺ CD8⁺ T cells 140 detected were minimal for each of the groups against any of the proteins, including for the Vx 141 groups against S peptides (Figure 1B), Expression of IL-4, IL-10, and CD107a by T cells showed. 142 in general, high variability, limiting the detection of differences (Supplemental Figure 3). 143 Nonetheless, S-specific degranulating CD107a⁺ CD8⁺ T cells were overall more frequent in the 144 Vx2 compared to the Ctrl group (P = 0.046; Supplemental Figure 3). Together, these data indicate 145 that M, N, and S-peptide specific IFN γ^+ CD4⁺ T cell responses can be readily detected in blood 146 months after resolving natural SARS-CoV-2 infection and that these responses require a recent 147 mRNA vaccine booster-dose against SARS-CoV-2 to elicit similar frequencies against the S 148 protein in vaccinated individuals.

149

mRNA vaccination induces S-specific CD4⁺ T cells in the lung 151

152 As reported previously⁸, we here found that mild or severe natural infection with SARS-CoV-2 153 induced robust IFN γ^+ CD4 $^+$ T cells in the lung against M, N, and S peptides, detectable for up to 154 12 months after infection (Figure 2A, B). Interestingly, whereas M and N-specific IFN γ^+ CD4⁺ T-155 cell frequencies were significantly higher in the Inf group compared to Ctrl or Vx groups, these 156 differences were not observed for S-specific responses (Figure 2A, B). Vx2 and Vx3 groups 157 showed presence of S-specific IFN γ^+ CD4⁺ T cells in the lung in most patients and its frequency 158 was comparable to levels detected in Inf patients, although statistical significance was no reached 159 compared to the Ctrl group (Figure 2B). In contrast to CD4⁺T cells, CD8⁺T cells producing IFN γ 160 after stimulation with M, N, or S peptides was variable within each group and did not result in 161 significant differences between the groups, indicating that natural infection nor vaccination elicit 162 a robust IFN_Y positive CD8⁺ T cell response in the human lung (Figure 2B). Furthermore, induction of lung anti-SARS-CoV-2-specific T-cell responses involving expression of IL-4, IL-10, and 163 164 CD107a did not differ between groups (Supplemental Figure 4A). Of note, in this tissue 165 compartment, we detected negative correlations between patient's age within the Inf group and 166 the frequency of S-specific degranulating CD4⁺ and CD8⁺ T cells (Spearman r = -0.76, P = 0.024and Spearman r = - 0.77, P = 0.020 respectively, Supplemental Figure 4B). 167

168 When we compared the magnitude of S-specific T cells in paired blood and lung samples, 169 we found increased frequencies of IFN γ^+ CD4⁺ T cells in the lungs of patients from the Inf group 170 compared to blood (P = 0.039, Figure 2C). The same trend was observed for the Vx individuals, 171 which was close to significant if both groups were pooled (P = 0.054), although this increase was 172 more variable as only 7 out of 12 Vx patients showed an increase, in contrast to 8 out of 9 Inf 173 patients. In contrast, the CD8⁺ T-cell compartment did not show clear differences between these 174 two compartments (Figure 2C), neither any of the T-cell subsets for any other function, which 175 were highly variable (Supplemental Figure 5). Together our data indicates that S-specific CD4⁺

176 T-cell responses are detectable in the lung of uninfected vaccinated patients, suggesting that 177 mRNA vaccination against SARS-CoV-2 may potentially elicit tissue-localized protective T-cell 178 responses already after the second mRNA vaccine dose.

179

180 Limited induction of tissue resident memory T cells by mRNA vaccination

181 Presence of T_{RM} cells may provide a better correlate of protection from disease in SARS-CoV-2 infected individuals and are characterized by expression of CD69 and/or CD103⁸⁹. Moreover, 182 183 T_{RM} cells require downregulation of the transcription factor T-bet for expression of CD103 and 184 their formation and survival at tissue sites ¹³. In order to assess if S-specific T cell responses 185 detected in Vx patients had indeed a T_{RM} phenotype, we analyzed expression of CD69 and CD103 186 by lung SARS-CoV-2-specific CD4⁺ and CD8⁺T cells, which we classified as: CD69⁻ (non- T_{RM}), 187 CD69⁺ (T_{RM}) and a subset within CD69⁺ cells expressing CD103⁺ (T_{RM} CD103⁺) (Figure 3A, 188 Supplemental Figure 2B for gating strategy). Additionally, we assessed expression of T-bet to 189 assure that CD69 in the lung was associated to a T_{RM} phenotype and not to activation of CD69⁻ T 190 cells or the product of residual blood in the lung. Both CD69⁺ T_{RM} and CD103⁺ T_{RM} subsets did 191 not show T-bet expression across all patient groups, whereas a fraction of CD69⁻ non-T_{RM} cells 192 presented T-bet expression (Supplemental Figure 2B), suggesting the association to tissue 193 residency when absent ⁸. S-specific CD4⁺ T cells from the Inf group showed higher frequencies 194 of IFN γ^+ cells within the CD69⁺ and CD103⁺ T_{RM} phenotypes (Figure 3A, B), with statistical 195 significance reached for the overall CD69⁺ T_{RM} fraction compared to the non-T_{RM} fraction. 196 Furthermore, while no significant differences were detected for CD103⁺ T_{RM} cells against S-197 peptides in any of the groups, a trend was observed for CD4⁺ T-cell responses to M peptides and 198 statistical significance was reached for CD8⁺ T cells against N peptides compared to the non-T_{RM} 199 fraction in the Inf group (Supplemental Figure 6A, B). Of note, a negative correlation was observed between IFN γ -secreting S-specific CD8⁺ CD103⁺ T_{RM} cells and sample timing (Spearman r = -200

2010.82, P = 0.019 Supplemental Figure 6C). In addition, some patients in the Vx2 and Vx3 groups202showed modest presence of S-specific T_{RM} with or without CD103 expression in their lungs203(Figure 3A, B). However, this response was highly heterogeneous and not statistically significant.204These findings indicate that mRNA vaccination against SARS-CoV-2 can induce S-specific T_{RM}205in some, but not all individuals and may also last long term after the second vaccination.

206

207 Overall functional T-cell response of lung and blood compartments

208 To better gain insight into the overall S-specific response by each group, including all functions 209 and considering lung-T_{RM} phenotypes, we represented S-specific CD4⁺ and CD8⁺ T cell subsets 210 as donut charts displaying the mean frequency of responses including all individuals (responders 211 and non-responders, Figure 4). This way, a dominance of IFNγ-secreting CD4⁺ T cells was 212 particularly associated to the two T_{RM} phenotypes in the Inf and, to a lesser extent, in the Vx2 213 patients (Figure 4A). Further, S-specific responses within non-T_{RM} and blood CD4⁺ T cells were 214 functionally similar and in general dominated by IFN γ and IL-4 secretion (Figure 4A). In contrast, 215 degranulation characterized the majority of lung S-specific CD8⁺ T cells from Inf individuals 216 (Figure 4B), which correlated negatively with older age for the T_{RM} fractions (Spearman r = -0.88, 217 P = 0.006 for both CD103 positive and negative. Supplemental Figure 6D). Degranulation was 218 also the major function in blood from the two Vx groups (Figure 4B). Last, in general, CD8⁺ T-cell 219 responses considering all functions were of higher magnitude in long-term Vx2 individuals, 220 reaching statistical significance for blood responses in comparison to the Ctrl group, as shown in 221 the adjoin graph on the right (Figure 4B).

222

223 Polyfunctional S-specific IFNγ⁺CD107a⁺ CD4⁺ T cells are absent in vaccinated patients

We previously detected a low but consistent polyfunctional IFN γ^+ CD107a⁺ T-cell response mostly associated to the T_{RM} fraction in convalescent infected patients ⁸. We therefore investigated

226 whether mRNA vaccination against SARS-CoV-2 would also induce such S-specific 227 polyfunctional responses in both compartments (Figure 5A, B). Indeed, increased frequencies of 228 polyfunctional IFN_γ⁺CD107a⁺ CD4⁺ T cells were detected in blood from the Inf group against N 229 peptides compared to the Ctrl group, but not against M- and S-peptides. Interestingly, a trend 230 towards higher frequencies of S-specific polyfunctional CD4⁺ T cells was observed for the Vx3 231 group (Figure 5A). Likewise, circulating polyfunctional S-specific CD8⁺ T cells were enhanced in 232 Vx2 individuals compared to Ctrl group (Figure 5A). In fact, if Vx groups were pooled to increase 233 sample size, then both CD4⁺ and CD8⁺ T cells reached significance compared to Ctrl samples (P 234 = 0.037 for CD4⁺ and P = 0.024 for CD8⁺). In addition, the frequency of polyfunctional 235 IFN_γ⁺CD107a⁺ cells present in total CD4⁺ and CD8⁺ T cells in the lung were only consistently increased in the Inf group against N peptides compared to the Ctrl and Vx3 groups (Figure 5B). 236 237 Nevertheless, while a high degree of variability was observed among vaccinated patients, 238 polyfunctional S-specific T cells were detected in some individuals (Figure 5B). Strikingly, S-239 specific CD4⁺ polyfunctional CD103⁺ T_{RM} cells were virtually absent in the Vx2 and Vx3 groups, 240 while being frequently present in the lungs of patients from the Inf group (Figure 6). Furthermore, 241 the frequency of S-specific polyfunctional CD4⁺ T cells in the CD69⁺ T_{RM} cells was higher in the 242 Inf group compared to the Ctrl and Vx2 groups (Figure 6). Together, these data indicate that both 243 short- and long-term vaccination do not induce S-specific IFNγ⁺CD107a⁺ CD103⁺ T_{RM} cells in the 244 lung, which may contribute to antiviral activity.

245

246 Anti-SARS-CoV-2 T cell response dynamics in two cases of interest

Last, considering the uniqueness of analyzing immune responses in paired blood and lung parenchyma samples and recent studies detailing changes in T cell responses in infected individuals already vaccinated and vice versa ¹⁴, we highlight two patients that were discarded due to not fitting inclusion criteria, yet bring interesting data to the study. HL174 was a patient in

251 their fifties who received the third mRNA-1273 vaccine boost and, five days after, tested positive 252 by PCR. We analyzed paired tissue samples 30 days after the boost/infection event 253 (Supplemental Figure 7A). This patient had a neutralization titer of 1740 IU/mL against omicron, 254 and had detectable IgG and Ig titers against S and N proteins (>800 AU/mL and 1.23 index, 255 respectively). When comparing T-cell responses from blood and lung tissue, a much higher IFNy-256 response was observed in the lung, in particular against the N protein, which already contained 257 responding cells with a T_{RM} phenotype (Supplemental Figure 7B, C). In contrast, in blood, 258 degranulation was enhanced mostly against S but also M protein and some proportion of IL-10 259 secretion was detected against all proteins (Supplemental Figure 7B).

260 On the other hand, patient HL162, who was in their early seventies, was first infected 261 presenting a mild COVID-19 and, several months after, received three doses of the mRNA-1273 262 vaccine. In this case, we obtained samples 3.7 months after infection and another one 1.3 months 263 after the third dose (due to a second intervention for a lung carcinoma), which corresponded to a 264 year after initial infection, as shown (Supplemental Figure 8A). Neither of these two time points 265 showed neutralization titers against omicron and the titers of IgG, instead of increasing after triple 266 vaccination, decreased from 156 to 0 index for the N protein and from 306.54 to 13.85 AU/mL for 267 S protein. The comparison of the tissue compartments after infection and after triple vaccination 268 evidenced a concomitant strong decrease in T-cell responses in blood and tissue (Supplemental 269 Figure 8B, C, and Supplemental Figure 9A, B). However, IFNγ-secreting SARS-CoV-2 T cells 270 against M and N proteins in the lung were better preserved from the original infection one year 271 later than were responses against the S protein enhanced due to vaccination (Supplemental 272 Figure 8B, C and Supplemental Figure 9A, B). Thus, while the lower respiratory tract compartment 273 more faithfully represented T_{RM} responses established already during the infection event one year 274 earlier, responses in blood mostly vanished.

275

276 **Discussion**

Comprehensive studies comparing the magnitude and duration of the T cell responses indicate 277 similar magnitude after dual vaccination and after natural SARS-CoV-2 infection ^{4, 11, 14}. However, 278 279 these results may not hold if we consider that the magnitude, the functional profile and even the 280 duration of these responses in blood may not faithfully reflect responses in the respiratory tract ⁶. 281 ^{8, 9, 15}. In fact, the individual comparison between these two compartments among the S-282 responding T cells from the different groups showed higher magnitude in the lung than in the 283 blood, but also a different profile. A key difference, and the main driver of our study, was the 284 establishment of long-term protection potentially mediated by T_{RM} after vaccination, since 285 longevity of SARS-CoV-2 T cell responses remains a critical question ⁶. In principle, T_{RM} are 286 established by mucosal infection since Ag together with local signals promote the recruitment and 287 establishment of this memory response. In this sense, intramuscular vaccination with an 288 adenovector vaccine in mice did not induce SARS-CoV-2-specific T_{RM} in their lungs ¹⁶. Thus, to 289 induce potent resident immunity, vaccine strategies may need to either use live-attenuated Ag or 290 employ mucosal routes. Consequently, the absence of vaccine induced S-specific T_{RM} could be 291 expected in infection-naïve individuals. Still, recent data shows that a secretory IgA response was 292 induced in ~30% of participants after two doses of a SARS-CoV-2 mRNA vaccine which, in addition, may play an important role in protection against infection ¹⁵. While we detected S-specific 293 294 IFN γ^+ CD4⁺ T cell responses in the lung of vaccinated individuals, the proportion of these cells in 295 the T_{RM} phenotype was modest, in particular if considering CD103 expression. Further, the 296 presence of polyfunctional IFN γ^+ CD107a $^+$ CD103 $^+$ T_{RM} appeared to be restricted to the lungs 297 of convalescent-infected patients only, while absent in the lungs of vaccinated patients.

Another difference in the comparison of the cellular immunity between SARS-CoV-2infected convalescent and uninfected-vaccinated individuals is the broader and potentially stronger response induced by symptomatic infection. This is partially manifested by the fact that

301 the overall magnitude of responses against M and N peptides are frequently higher than S 302 peptides ^{8, 17, 18, 19}. Of note, disease severity may impact both the magnitude and function of the T cell response against the different proteins ^{8, 20, 21}. In addition, among other factors, age also 303 influences the magnitude and duration of immune responses in distinct tissue compartments, 304 305 even the establishment of T_{RM}^{22} , a factor that influenced the frequency of degranulation in the 306 lung of our Inf patients, including within the T_{RM} fraction. Yet advanced age will also limit the 307 immune response to vaccination ²³. On the other hand, we have observed that different proteins 308 induce different functional profiles during acute infection, which may influence disease control⁸. 309 S-specific immune responses may better support B cell and antibody generation via follicular 310 helper T cells, which are instrumental to limiting infection ^{4, 8}. Instead, responses against the N 311 protein seem to more consistently induce polyfunctional antiviral T cells and these responses may 312 be more conserved among other coronaviruses ^{5, 8, 24, 25}. Indeed, preexisting SARS-CoV-2 specific 313 T cell responses have been found in the blood of unexposed individuals ^{18, 26}. In this sense, in our 314 study we detected a low level of preexisting T cell responses in our control group mostly located 315 in the lung, which may be in agreement with a recent report in tonsillar tissue ²⁷. Thus, another 316 conclusion would be highlighting the interest of including other proteins beyond the spike such as N sequences, which has been suggested before ^{5, 8, 19, 25, 28}. Last, in terms of duration, our study 317 318 lacks longitudinal data to assess the dynamics in the different compartments, yet it is assumed that T_{RM} phenotypes will contribute to long-term persistence ^{6, 8, 29}. In fact, the only patient for 319 320 which we had longitudinal sampling after infection and after the third vaccine boost (Supplemental 321 Figure 8) demonstrated that even if vaccination fails to induce a systemic antibody response, a 322 low frequency SARS-CoV-2 T cell response directed to proteins from the original infection 323 remains exclusively detectable in the lung as T_{RM} one year after.

The overall CD8⁺ T cell response was enhanced in some but not all vaccinated patients and was in general low and dominated by degranulation. In fact, lung S-specific CD8⁺ T_{RM}

326 presented similar overall frequencies in vaccinated individuals when considering all functions. Of 327 note, low percentages of SARS-CoV-2 specific CD8⁺ T cells may be due to the use of 15-mer peptides, which are less optimal than 9/10-mer peptides for HLA class I binding³, although this is 328 329 debatable²¹. Other methods, such as the use of activation induced markers and tetramers loaded 330 with SARS-CoV-2 immunodominant peptides ^{27, 30} may give additional insight into the CD8⁺ T cell 331 response against SARS-CoV-2. Thus, considering the putative protective role of CD8⁺ T cells observed in animal models ²⁹, further exploration of the CD8⁺ T cell response after mRNA 332 333 vaccination is warranted, our results for these vaccinated individuals are certainly encouraging.

334 We acknowledge that our study has several limitations. The small sample size for the 335 different groups warrants further investigation with ideally larger cohorts. Finding patients that 336 meet our inclusion criteria was however challenging and currently, patients meeting the criteria 337 are no longer available. In addition, we addressed T cell immune responses in older and mostly 338 oncologic patients. In general, T cell responses of cancer patients after vaccination against SARS-339 CoV-2 may be impaired ³¹, which may overall underestimate immune responses in all groups of 340 our study. However, we still detect vaccine-induced S-specific CD4⁺T cells in our patients, which 341 shows that mRNA vaccination may even contribute to protection against COVID-19 in these 342 vulnerable patients. Further, the Inf group consisted of patients recovered from mild or severe 343 disease. Even if age and underlying conditions were similar to the other groups, disease severity 344 may have skewed frequencies of SARS-CoV-2-specific T cells towards the higher end. Still, 345 considering their age and condition, any of these patients with a new infection would most likely 346 develop a more serious COVID-19 event compared to the general population. In addition, the 347 boosted Vx3 group was sampled short term comparing to the Vx2 group, but enhancement of T 348 cell responses would be better detected 5-10 days after boosting ^{10, 11} (which was a less likely 349 time for scheduling surgery). Still it was enough time to suggest that there was no major 350 enhancement of long-term durable T cell response in the lung by a third boost. Further, we did

not assess the contribution of T cells targeting mutation regions to the total spike since we aimed to compare the strength and function of vaccinated and naturally infected patients (these last group obtained during the first wave). However, the overall contribution of T cell responses to mutational regions/total spike responses has been reported to be low ^{14, 32}.

355 Overall, our results contribute to the understanding of disease protection mediated by 356 current mRNA vaccines. While our data indicate a more robust and broader cellular response in 357 convalescent patients, S-specific T cells can be detected in the lung of vaccinated individuals to 358 similar overall levels 8 months after immunization, highlighting the durability of this immune arm. 359 Further, while we detected increased levels of IFN γ^+ T cell responses in blood after the third dose, 360 limited benefit of boosting towards the enhancement of T cell responses in the lung was evidenced 361 by our data. However, elderly people not responding to vaccination have been shown to benefit 362 from a third dose ²³ and there is an obvious benefit of boosting to provide a higher degree of antibody-mediated protection from infection in the context of high incidence of VOC¹. Still, if virus 363 neutralization is unable to completely block infection, a more robust and broader T_{RM} response 364 365 established in the lung of convalescent-infected individuals may have more chances of limiting 366 disease. In this sense, polyfunctional CD107a⁺ IFN γ^+ cells may contribute to infection clearance 367 or even limit the occurrence of breakthrough SARS-CoV-2 infections vaccination and absence of 368 these cells in vaccinated patients underlines the need for the development of mucosal vaccines ³³, recently shown to be effective in inducing sterilizing immunity in mice ³⁴. The inclusion of other 369 protein fragments such as nucleocapsid peptides ^{5, 8, 19, 25, 28} in combination with mucosal routes 370 371 ³⁵ will likely contribute to the establishment of optimal memory T cells in future vaccine strategies.

- 372
- 373374
- 571
- 375

376 Methods

377

378 Ethics statement

This study was performed in accordance with the Declaration of Helsinki and approved by the corresponding Institutional Review Board (PR(AG)212/2020) of the Vall d'Hebron University Hospital (HUVH), Barcelona, Spain. Written informed consent was provided by all patients recruited to this study.

383

384 Subject recruitment and sample collection

385 Patients undergoing lung resection for various reasons at the HUVH were recruited through the 386 Thoracic Surgery Service and invited to participate. Initially, a total of 32 patients, from whom 387 paired blood samples and lung biopsies were collected were assayed. However, based on 388 vaccination and/or infection status of the recruited patients, 26 (+2: HL174 and HL162) patients 389 were finally included. Supplemental Table 1 summarizes relevant information from included 390 patients. For all participants, whole blood was collected with EDTA anticoagulant. Plasma was collected and stored at -80 °C (except for 4 patients distributed among the different groups, as 391 392 indicated in Supplemental Table 1, for which this sample was not available) and PBMCs were 393 isolated via Ficoll-Pague separation and processed immediately for stimulation assays.

394

395 Phenotyping and Intracellular Cytokine Staining of lung biopsies

Immediately following surgery, healthy areas from patients undergoing lung resection were collected in antibiotic-containing RPMI 1640 medium and processed as published⁸. Briefly, 8-mm³ dissected blocks were first enzymatically digested with 5 mg/ml collagenase IV (Gibco) and 100µg/ml of DNase I (Roche) for 30 min at 37 °C and 400 rpm and, then, mechanically digested with a pestle. The resulting cellular suspension was first filtered through a 70µm pore size cell strainer and then filtered through a 30µm pore size cell strainer (Labclinics). After washing with

402 PBS, cells were stimulated in a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL 403 of SARS-CoV-2 peptides (PepTivator SARS-CoV-2 M, N or S, Miltenyi Biotec) in the presence of 404 3.3μL/mL α-CD28/CD49d (clones L293 and L25), 0.55μL/mL Brefeldin A, 0.385μL/mL Monensin 405 and 5 µL/100µL anti-CD107a-PE-Cy5 (all from BD Biosciences). For each patient, a negative 406 control, cells treated with medium, and positive control, cells incubated in the presence of 0.4nM 407 PMA and 20µM lonomycin, were included. Next day, cellular suspensions were stained with 408 Live/Dead Aqua (Invitrogen) and anti-CD103 (FITC, Biolegend), anti-CD69 (PE-CF594, BD 409 Biosciences), anti-CD40 (APC-Cy7, Biolegend), anti-CD8 (APC, BD Biosciences), anti-CD3 410 (BV650, BD Biosciences) and anti-CD45 (BV605, BD Biosciences) antibodies. Cells were 411 subsequently fixed and permeabilized using the FoxP3 Fix/Perm kit (BD Biosciences) and stained 412 with anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences), anti-T-bet (BV421, 413 Biolegend) and anti-IFN_γ (AF700, Invitrogen) antibodies. After fixation with PBS 2% PFA, cells 414 were acquired in a BD LSR Fortessa flow cytometer (Cytomics Platform, High Technology Unit, 415 Vall d'Hebron Institut de Recerca).

416

417 Phenotyping and Intracellular Cytokine Staining in blood

418 Freshly isolated PBMCs were labelled for CCR7 (PE-CF594, BD Biosciences) and CXCR3 419 (BV650, BD Biosciences) for 30 min at 37°C. After washing with PBS, PBMCs were stimulated in 420 a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL of SARS-CoV-2 peptides 421 together with the same concentration of Brefeldin A, Monensin, α -CD28/CD49d and CD107a-PE-422 Cy5, as stated for the lung suspension above and published before⁸. For each patient, a negative 423 control and a positive control were also included. After stimulation, cells were washed twice with 424 PBS and stained with Aqua LIVE/DEAD fixable dead cell stain kit (Invitrogen). Cell surface 425 antibody staining included anti-CD3 (Per-CP), anti-CD4 (BV605) and anti-CD56 (FITC) (all from 426 BD Biosciences). Cells were subsequently fixed and permeabilized using the Cytofix/Cytoperm

kit (BD Biosciences) and stained with anti-Caspase-3 (AF647, BD Biosciences), anti-Bcl-2
(BV421, Biolegend), anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences) and antiIFNg (AF700, Invitrogen) for 30 mins. Cells were then fixed with PBS 2% PFA and acquired in a
BD LSR Fortessa flow cytometer.

431

432 SARS-CoV-2 serology

433 The serological status of patients included in this study was determined in serum samples using 434 two commercial chemiluminescence immunoassays (CLIA) targeting specific SARS-CoV-2 435 antibodies: (1) Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Mannheim, Germany) was 436 performed on the Cobas 8800 system (Roche Diagnostics, Basel, Switzerland) for the 437 determination of total antibodies (including IgG, IgM, and IgA) against nucleocapsid (N) SARS-438 CoV-2 protein; and (2) Liaison SARS-CoV-2 TrimericS IgG (DiaSorin, Stillwater, MN) was 439 performed on the LIAISON XL Analyzer (DiaSorin, Saluggia, Italy) for the determination of IgG 440 antibodies against the spike (S) glycoprotein.

441

442 **Pseudovirus neutralization assay**

443 The spike of the Omicron SARS-CoV-2 was generated (GeneArt Gene Synthesis, ThermoFisher 444 Scientific) from the plasmid containing the D614G mutation with a deletion of 19 amino acids, 445 which was modified to include the mutations specific for this VOC (A67V, Δ69-70, T95I, 446 G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, 447 G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, 448 N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) (kindly provided by Drs. J. Blanco and B. Trinite). Pseudotyped viral stocks of VSV*ΔG(Luc)-S were generated following the 449 450 protocol described in³⁶. Briefly, 293T cells were transfected with 3µg of the omicron plasmid 451 (pcDNA3.1 omicron). Next day, cells were infected with a VSV-G-Luc virus (MOI=1) for 2h and 452 washed twice with warm PBS. To neutralize contaminating VSV* $\Delta G(Luc)$ -G particles cells were

453 incubated overnight in media containing 10% of the supernatant from the I1 hybridoma (ATCC 454 CRL-2700), containing anti-VSV-G antibodies. Next day, viral particles were harvested and 455 titrated in VeroE6 cells by enzyme luminescence assay (Britelite plus kit; PerkinElmer). For the 456 neutralization assays, VeroE6 cells were seeded in 96-well white, flat-bottom plates (Thermo 457 Scientific) at 30,000 cells/well. Plasma samples were heat-inactivated and diluted four-fold 458 towards a concentration of 1/32 of the initial sample. Diluted plasma samples were then incubated 459 with pseudotyped virus (VSV* Δ G(Luc)-S^{omicron}) with titers of approximately 1x10⁶ – 5x10⁵ RLUs/ml 460 of luciferase activity - in a 96 well-plate flat bottom for 1 hour at 37°C, 5% CO₂. Next, 30,000 Vero 461 E6 cells were added to each well and incubated at 37°C, 5% CO₂ for 20-24 hours. Then, viral 462 entry was measured by the expression of luciferase. Cells were incubated with Britelite plus 463 reagent (Britelite plus kit; PerkinElmer) and then transferred to an opaque black plate. 464 Luminescence was immediately recorded by a luminescence plate reader (LUMIstar Omega). 465 Viral neutralization was calculated as the reciprocal plasma dilution (ID50) resulting in a 50% 466 reduction in relative light units. If no neutralization was observed, an arbitrary titer value of 16 (half 467 of the limit of detection [LOD]) was reported.

468

469 Statistical analyses

470 Flow cytometry data was analyzed using FlowJo v10.7.1 software (TreeStar). Data and statistical 471 analyses were performed using Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Data shown 472 in bar graphs were expressed as median and Interquartile range (IQR), unless stated otherwise. 473 Correlation analyses were performed using non-parametric Spearman rank correlation. Kruskal-474 Wallis rank-sum test with Dunn's post-hoc test was used for multiple comparisons. Friedmann test with Dunn's post-hoc test was applied for paired comparisons. A P value <0.05 was 475 476 considered statistically significant. Antigen-specific T-cell data was calculated as the net 477 frequency, where the individual percentage of expression for a given molecule in the control

- 478 condition (vehicle) was subtracted from the corresponding SARS-CoV-2-peptide stimulated479 conditions.
- 480
- 481 **Data availability**
- 482 The data that support the findings of this study are available from the corresponding author upon
- 483 reasonable request.

References

484	1.	Cromer D, et al. Neutralising antibody titres as predictors of protection against
485		SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet
486		<i>Microbe</i> 3 , e52-e61 (2022).
487		
488	2.	Geers D, et al. SARS-CoV-2 variants of concern partially escape humoral but not
489		T-cell responses in COVID-19 convalescent donors and vaccinees. Science
490		immunology 6 , (2021).
491		
492	3.	Keeton R, et al. T cell responses to SARS-CoV-2 spike cross-recognize
493		Omicron. <i>Nature</i> 603 , 488-492 (2022).
494		
495	4.	Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 23,
496		186-193 (2022).
497		

498	5.	Kundu R, et al. Cross-reactive memory T cells associate with protection against
499		SARS-CoV-2 infection in COVID-19 contacts. Nature communications 13, 80
500		(2022).
501		
502	6.	Niessl J, Sekine T, Buggert M. T cell immunity to SARS-CoV-2. Seminars in
503		<i>immunology</i> 55 , 101505 (2021).
504		
505	7.	Jung JH, et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19
506		convalescent patients for 10 months with successful development of stem cell-
507		like memory T cells. Nature communications 12, 4043 (2021).
508		
509	8.	Grau-Exposito J, et al. Peripheral and lung resident memory T cell responses
510		against SARS-CoV-2. Nature communications 12, 3010 (2021).
511		
512	9.	Szabo PA, et al. Longitudinal profiling of respiratory and systemic immune
513		responses reveals myeloid cell-driven lung inflammation in severe COVID-19.
514		Immunity 54 , 797-814 e796 (2021).
515		
516	10.	Goel RR, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2
517		and variants of concern. Science 374, abm0829 (2021).
518		
519	11.	Zhang Z, et al. Humoral and cellular immune memory to four COVID-19
520		vaccines. bioRxiv : the preprint server for biology, (2022).

521

522	12.	Ortega N, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-
523		existing antibodies to human coronaviruses. Nature communications 12, 4740
524		(2021).
525		
526	13.	Laidlaw BJ, et al. CD4+ T cell help guides formation of CD103+ lung-resident
527		memory CD8+ T cells during influenza viral infection. Immunity 41, 633-645
528		(2014).
529		
530	14.	Minervina AA, et al. SARS-CoV-2 antigen exposure history shapes phenotypes
531		and specificity of memory CD8 T cells. medRxiv : the preprint server for health
532		sciences, (2022).
533		
534	15.	Sheikh-Mohamed S, et al. Systemic and mucosal IgA responses are variably
535		induced in response to SARS-CoV-2 mRNA vaccination and are associated with
536		protection against subsequent infection. Mucosal immunology, (2022).
537		
538	16.	Hassan AO, et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and
539		Lower Respiratory Tracts against SARS-CoV-2. Cell 183, 169-184 e113 (2020).
540		
541	17.	Le Bert N, et al. Highly functional virus-specific cellular immune response in
542		asymptomatic SARS-CoV-2 infection. The Journal of experimental medicine 218,
543		(2021).

544

545	18.	Grifoni A, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
546		Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489-
547		1501 e1415 (2020).
548		
549	19.	Taus E, et al. Dominant CD8(+) T Cell Nucleocapsid Targeting in SARS-CoV-2
550		Infection and Broad Spike Targeting From Vaccination. Front Immunol 13,
551		835830 (2022).
552		
553	20.	Demaret J, et al. Severe SARS-CoV-2 patients develop a higher specific T-cell
554		response. Clinical & translational immunology 9, e1217 (2020).
555		
556	21.	Thieme CJ, et al. Robust T Cell Response Toward Spike, Membrane, and
557		Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical
558		
550		COVID-19 Patients. Cell reports Medicine 1, 100092 (2020).
559		COVID-19 Patients. Cell reports Medicine 1, 100092 (2020).
559 560	22.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML, <i>et al.</i> Heterogeneity of human anti-viral immunity shaped by virus,
559560561	22.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML, <i>et al.</i> Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. <i>Cell reports</i> 37 , 110071 (2021).
 559 560 561 562 	22.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML <i>, et al.</i> Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. <i>Cell reports</i> 37 , 110071 (2021).
 559 560 561 562 563 	22. 23.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML <i>, et al.</i> Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. <i>Cell reports</i> 37 , 110071 (2021). Romero-Olmedo AJ <i>, et al.</i> Induction of robust cellular and humoral immunity
 559 560 561 562 563 564 	22. 23.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML, <i>et al.</i> Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. <i>Cell reports</i> 37 , 110071 (2021). Romero-Olmedo AJ, <i>et al.</i> Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously
 559 560 561 562 563 564 565 	22. 23.	COVID-19 Patients. <i>Cell reports Medicine</i> 1 , 100092 (2020). Poon MML, <i>et al.</i> Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. <i>Cell reports</i> 37 , 110071 (2021). Romero-Olmedo AJ, <i>et al.</i> Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. <i>Nature microbiology</i> 7 , 195-199 (2022).

567	24.	Matchett WE, et al. Cutting Edge: Nucleocapsid Vaccine Elicits Spike-
568		Independent SARS-CoV-2 Protective Immunity. Journal of immunology 207, 376-
569		379 (2021).
570		
571	25.	Peng Y, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response
572		controls viral replication and is associated with less severe COVID-19 disease.
573		Nat Immunol 23 , 50-61 (2022).
574		
575	26.	Braun J, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with
576		COVID-19. <i>Nature</i> , (2020).
577		
578	27.	Niessl J, et al. Identification of resident memory CD8(+) T cells with functional
579		specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. Sci
580		<i>Immunol</i> 6 , eabk0894 (2021).
581		
582	28.	Mazzoni A, et al. First-dose mRNA vaccination is sufficient to reactivate
583		immunological memory to SARS-CoV-2 in subjects who have recovered from
584		COVID-19. The Journal of clinical investigation 131 , (2021).
585		
586	29.	Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to
587		respiratory coronaviruses. Immunologic research 59, 118-128 (2014).
588		

589	30.	Saini SK, et al. SARS-CoV-2 genome-wide T cell epitope mapping reveals
590		immunodominance and substantial CD8(+) T cell activation in COVID-19
591		patients. <i>Sci Immunol</i> 6 , (2021).
592		
593	31.	Fendler A, et al. COVID-19 vaccines in patients with cancer: immunogenicity,
594		efficacy and safety. Nat Rev Clin Oncol 19, 385-401 (2022).
595		
596	32.	Skelly DT, et al. Two doses of SARS-CoV-2 vaccination induce robust immune
597		responses to emerging SARS-CoV-2 variants of concern. Nature
598		<i>communications</i> 12 , 5061 (2021).
599		
600	33.	Topol EJ, Iwasaki A. Operation Nasal Vaccine-Lightning speed to counter
601		COVID-19. <i>Sci Immunol</i> , eadd9947 (2022).
602		
603	34.	Tang J, et al. Respiratory mucosal immunity against SARS-CoV-2 following
604		mRNA vaccination. Sci Immunol, eadd4853 (2022).
605		
606	35.	Mao T, et al. Unadjuvanted intranasal spike vaccine booster elicits robust
607		protective mucosal immunity against sarbecoviruses. bioRxiv : the preprint server
608		for biology, (2022).
609		
610	36.	Grau-Exposito J, et al. Evaluation of SARS-CoV-2 entry, inflammation and new
611		therapeutics in human lung tissue cells. PLoS pathogens 18, e1010171 (2022).
612		

613 Author contributions

- 614 Conceptualization, M.G.; Patient Recruitment and Sample Collection, J.R., V.F.; Methodology,
- 615 DKJ.P., SG.K., A.G.R., J.R-C, C.M., J.E.; Investigation, DKJ.P., SG.K., A.G.R., J.E.; Formal
- 616 Analysis, DKJ.P., A.G.R., M.J.B. and M.G.; Writing-Original Draft, DKJ.P. and M.G; Writing-
- 617 Review & Editing, all authors; Funding Acquisition, M.G.; Supervision, M.G.
- 618

619 Acknowledgements

620 We would like to thank all the patients who participated in the study and Drs. Julià Blanco and 621 Benjamin Trinite for providing the plasmid encoding the omicron spike. This work was supported 622 by grants from Fundació La Marató TV3 (201814-10 FMTV3 and 202112-30 FMTV3), from the 623 Health department of the Government of Catalonia (DGRIS 1 5), and the Spanish AIDS network 624 Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007). M.J.B is supported by 625 the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). The 626 funders had no role in study design, data collection and analysis, the decision to publish, or 627 preparation of the manuscript.

Competing interests

The authors declare no competing interests.

629 FIGURES AND FIGURE LEGENDS

630 Figure 1





631 Figure 1. SARS-CoV-2-specific T-cell responses in peripheral blood from convalescent and 632 vaccinated patients. (A) Representative flow-cytometry plots showing CD4⁺ T cells expressing 633 CD107a and IFNy after exposure of whole PBMCs to S-peptide pools or left unstimulated for each 634 of the four groups included in this study (complete gating strategy is shown in Supplemental 635 Figure 2A). (B) Comparison of the net frequency (background subtracted) of IFN γ^+ cells within 636 CD4⁺ (upper) and CD8⁺ (lower) T-cell subsets after stimulation of PBMCs with any of the three 637 viral peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). Data are shown as 638 median ± IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; 639 Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). 640 Statistical significance was determined by Kruskal-Wallis test (with Dunn's post-test).

641 Figure 2



642 Figure 2. SARS-CoV-2-specific lung T-cell responses from convalescent and vaccinated 643 patients and comparison between tissue compartments. (A) Representative flow-cytometry 644 plots showing CD4⁺ T cells expressing CD107a and IFN_Y after exposure of single-cell 645 suspensions of lung tissue to S-peptide pools or left unstimulated for each of the four groups 646 included in this study (complete gating strategy is shown in Supplemental Figure 2B). (B) 647 Comparison of the net frequency (background subtracted) of IFN γ^+ cells within CD4⁺ (upper) and 648 CD8⁺ (lower) T-cell subsets after exposure of lung single-cell suspensions to any of the three viral 649 peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). (C) Comparison of the 650 net frequency of IFN γ^+ cells within CD4⁺ (left) and CD8⁺ (right) T-cell subsets in paired blood and 651 lung samples of each group after exposure to S-peptide pools. Data in bar graphs are shown as 652 median \pm IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; 653 Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). 654 Statistical significance was determined by (B) Kruskal-Wallis test (with Dunn's post-test) or (C) 655 Friedmann test (with Dunn's post-test).

657 **Figure 3**



Figure 3. Frequency of Spike-specific T_{RM} **cells in the lung.** (**A**) Representative flow-cytometry plots showing three subsets of CD4⁺ T cells present in the lung: CD69⁻ non-T_{RM}, CD69⁺ T_{RM}, and CD69⁺CD103⁺ T_{RM} cells expressing CD107a and IFN_{γ} after exposure of single-cell suspensions of lung tissue to S-peptide pools or left unstimulated for an Inf and a Vx2 patients. (**B**) Comparison of the net frequency of S-specific IFN_{γ}⁺ cells within the three (non-) T_{RM} cell subsets present in the lung for each group. Data in bar graphs are shown as median ± IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=8;

666 Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=4). Statistical significance was
667 determined by Friedmann test (with Dunn's post-test) for the difference between the cellular
668 subsets within each patient group.

669 **Figure 4**



Figure 4. Overall functional T-cell response of lung and blood compartments. (A, B) Donut 670 671 charts displaying the net contribution of each functional marker (IFNγ, CD107a, IL-4, and IL-10) 672 to the overall S-specific CD4⁺ (A) and CD8⁺ (B) T-cell response within the lung resident and non-673 resident T-cell subsets and in peripheral blood for each of the individual patient groups. Data 674 represent the mean value of the net frequency of each function within the patient group, including 675 both responders and non-responders. The frequency shown inside each donut chart represents 676 the accumulated mean response of all functions. Bar charts on the right show the mean of the 677 total frequency considering all functions per group (mean ± SD). Statistical significance was 678 determined by Kruskal-Wallis test (with Dunn's post-test) for the difference between each group. 679 * *P* < 0.05.

680 **Figure 5**

а



b



681	Figure 5. Polyfunctional CD4 ⁺ and CD8 ⁺ T-cell responses in blood and lung of convalescent
682	and vaccinated patients. (A, B) Comparison of the net frequency of polyfunctional CD107a+
683	IFN γ^{+} cells within CD4 ⁺ and CD8 ⁺ T-cell subsets for each of the four groups after exposure of
684	PBMCs (A) or single-cell suspensions of lung tissue (B) to any of the three viral peptide pools
685	(membrane (M), nucleocapsid (N) and spike (S) peptides). Data in bar graphs are shown as
686	median ± IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5;
687	Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5).
688	Statistical significance was determined by was determined using Kruskal-Wallis test (with Dunn's
689	post-test).
690	
691	

694 Figure 6



695

696 Figure 6. Frequency of polyfunctional T-cell responses against spike with a tissue-resident 697 phenotype in the lung. Comparison of the net frequency of S-specific polyfunctional CD107a⁺ 698 IFN γ^+ cells within lung CD4⁺ (upper) and CD8⁺ (lower) (non-) tissue-resident cell subsets (CD69⁻ 699 non-T_{RM}, CD69⁺ T_{RM}, and CD69⁺CD103⁺ T_{RM} cells) for each of the four patient groups after 700 exposure of single-cell lung suspensions to S-peptide pools. Data in bar graphs are shown as 701 median ± IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; 702 Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=4). 703 Statistical significance was determined by Kruskal-Wallis test (with Dunn's post-test) for the 704 difference between the groups.